SCHEMBL589633

SCHEMBL589633

NC(=O)c1cccc(S(=O)(=O)c2ccccc2)c1N

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 6/20 0.53
ALDH1A1 P00352 2/20 0.49
IKBKB O14920 2/20 0.45
MMP2 P08253 2/20 0.44
MMP3 P08254 2/20 0.44
MMP9 P14780 2/20 0.44
MMP8 P22894 2/20 0.44
MMP12 P39900 2/20 0.44
MMP13 P45452 2/20 0.44
MMP14 P50281 2/20 0.44
MMP16 P51512 2/20 0.44
MMP1 P03956 1/20 0.44
KDM4E B2RXH2 2/20 0.43
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41
TSHR P16473 1/20 0.41
HTT P42858 1/20 0.41
F2 P00734 1/20 0.41
PRSS1 P07477 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10589344 0.88 HTR6 (0.55) HTR6ALDH1A1MMP2MMP3MMP9
SCHEMBL10582655 0.87 ALDH1A1 (0.49) HTR6ALDH1A1IKBKBMMP2MMP3
SCHEMBL364480 0.86 HTR6 (0.55) HTR6ALDH1A1MMP2MMP3MMP9
SCHEMBL8369355 0.81 KDM4E (0.59) HTR6ALDH1A1MMP2MMP3MMP9
SCHEMBL15641524 0.79 TTR (0.47) ALDH1A1IKBKBKDM4ETSHRF2
SCHEMBL8637433 0.78 HTR6 (0.44) HTR6ALDH1A1IKBKBMMP2MMP3
SCHEMBL27492085 0.78 HTR6 (0.54) HTR6ALDH1A1MMP2MMP3MMP9
SCHEMBL8517076 0.77 BCAT2 (0.44) ALDH1A1IKBKBKDM4ETSHRF2
SCHEMBL28945397 0.77 KEAP1 (0.40) ALDH1A1KDM4ETSHRF2PRSS1
SCHEMBL564663 0.77 HTR6 (0.58) HTR6ALDH1A1KDM4ENPSR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101594862-B Substituted indazole derivatives as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-11-25 CN disclosed
EP-2120932-B1 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER NERVIANO MEDICAL SCIENCES SRL (IT) 2014-07-09 EP disclosed
US-8114865-B2 Indazole derivatives as kinase inhibitors for the treatment of cancer NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-02-14 US disclosed
US-20100197665-A1 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-08-05 US disclosed
EP-2120932-A1 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER Nerviano Medical Sciences S.r.l. (IT) 2009-11-25 EP disclosed
WO-2008074749-A9 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER NERVIANO MEDICAL SCIENCES SRL (IT) 2009-05-07 WO disclosed
WO-2008074749-A1 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197665-A1 INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER MAP3K5, MAP3K19, MAP3K3 HTR6 3756/4885ALDH1A1 1771/4885IKBKB 310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.